The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Serotonin-dopamine interaction and its relevance to schizophrenia
Abstract
OBJECTIVE: The therapeutic success of clozapine and risperidone has focused attention on the interaction between serotonin and dopamine systems as an avenue for superior therapeutics in schizophrenia. The authors review the neurobiological basis for this interaction and its clinical relevance. METHOD: The authors synthesized information from more than 100 published articles obtained through electronic and bibliography-directed searches. FINDINGS: The serotonin system inhibits dopaminergic function at the level of the origin of the dopamine system in the midbrain as well as at the terminal dopaminergic fields in the forebrain. Serotonergic antagonists release the dopamine system from this inhibition. This disinhibition of the dopamine system in the striatum may alleviate neuroleptic-induced extrapyramidal symptoms, and a similar disinhibition in the prefrontal cortex may ameliorate negative symptoms. However, the benefits of combined serotonergic-dopaminergic blockade may be observed in only a narrow dose range and may be lost with doses that produce suprathreshold dopaminergic blockade. CONCLUSIONS: Serotonergic modulation of dopaminergic function provides a viable mechanism for enhancing therapeutics in schizophrenia, but much remains unclear. Future research will have to establish the existence of this interaction in humans in vivo, specify the conditions under which it leads to optimal therapeutic benefits, and explore the possibility of using specific serotonergic treatments as flexible adjuncts to typical neuroleptics, rather than the present trend toward using single drugs with combined actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of the brain serotonin system
Jacobs, B. L., & Azmitia, E. C. (1992) · Physiological Reviews · doi:10.1152/physrev.1992.72.1.165 · Cited by 2,576
Serotonin, schizophrenia and antipsychotic drug action
Breier, A. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(94)00043-8 · Cited by 174
The Central 5‐HT1A Receptors: Pharmacological, Biochemical, Functional, and Regulatory Propertiesa
Hamon, M., GOZLAN, H., Mestikawy, S. E., Emerit, M. B., Bolaños, F. J., & Schechter, L. E. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16877.x · Cited by 144
Cited by
The neuropathology of schizophrenia
Harrison, P. J. (1999) · Brain · doi:10.1093/brain/122.4.593 · Cited by 1,677
The association of sleep and pain: an update and a path forward
Finan, P. H., Goodin, B. R., & Smith, M. T. (2013) · The Journal of Pain · doi:10.1016/j.jpain.2013.08.007 · Cited by 1,620
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Self-citationKapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Self-citationReview: Carbon nanotube based electrochemical sensors for biomolecules
Jacobs, C. B., Peairs, M. J., & Venton, B. J. (2010) · Analytica Chimica Acta · doi:10.1016/j.aca.2010.01.009 · Cited by 987
Opponent interactions between serotonin and dopamine
Daw, N. D., Kakade, S., & Dayan, P. (2002) · Neural Networks · doi:10.1016/s0893-6080(02)00052-7 · Cited by 844
Neuroanatomical and Neurochemical Substrates of Timing
Coull, J. T., Cheng, R.-K., & Meck, W. H. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.113 · Cited by 808
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
The reinterpretation of dreams: An evolutionary hypothesis of the function of dreaming
Revonsuo, A. (2000) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00004015 · Cited by 676
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
Neuroscience of apathy and anhedonia: a transdiagnostic approach
Husain, M., & Roiser, J. P. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0029-9 · Cited by 640
Frank, M. J., & Claus, E. D. (2006) · Psychological Review · doi:10.1037/0033-295x.113.2.300 · Cited by 585
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
Seo, D., Patrick, C. J., & Kennealy, P. J. (2008) · Aggression and Violent Behavior · doi:10.1016/j.avb.2008.06.003 · Cited by 520
The pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465
Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia
Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., & H??schl, C. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00004 · Cited by 461
Opponency revisited: competition and cooperation between dopamine and serotonin
Boureau, Y.-L., & Dayan, P. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.151 · Cited by 456
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Schizophrenia, “Just the Facts”: What we know in 2008
Tandon, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.022 · Cited by 409
Kapur, S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.553 · Cited by 396
Weiner, I. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1313-x · Cited by 391
Serotonin in Affective Control
Dayan, P., & Huys, Q. J. M. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135607 · Cited by 381
5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370
“In patients this characteristic manifests itself as greater than 80% 5-HT2 occupancy along with less than 80% D2 occupancy (3, 4).”
BackgroundSelf-citationObsessive-Compulsive Disorder as a Disturbance of Security Motivation.
Szechtman, H., & Woody, E. (2004) · Psychological Review · doi:10.1037/0033-295x.111.1.111 · Cited by 370
Schizophrenia, “just the facts”: What we know in 2008Part 3: Neurobiology
KESHAVAN, M., TANDON, R., BOUTROS, N., & NASRALLAH, H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.020 · Cited by 347
Serotonin and brain development
Sodhi, M. S. K., & Sanders-Bush, E. (2004) · International Review of Neurobiology · doi:10.1016/s0074-7742(04)59006-2 · Cited by 340
Pathophysiology of obsessive–compulsive disorder
Aouizerate, B., Guehl, D., Cuny, E., Rougier, A., Bioulac, B., Tignol, J., & Burbaud, P. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.02.004 · Cited by 341
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia
Kapur, S., & Remington, G. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.503 · Cited by 324
Self-citationCelada, P., Bortolozzi, A., & Artigas, F. (2013) · CNS Drugs · doi:10.1007/s40263-013-0071-0 · Cited by 323
Swamy, B. E. K., & Venton, B. J. (2007) · The Analyst · doi:10.1039/b705552h · Cited by 314
Vollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305
De Deurwaerdère, P., Navailles, S., Berg, K. A., Clarke, W. P., & Spampinato, U. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0112-04.2004 · Cited by 306
The serotonergic system and cognitive function
Švob Štrac, D., Pivac, N., & Mück-Šeler, D. (2016) · Translational Neuroscience · doi:10.1515/tnsci-2016-0007 · Cited by 285
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Yang, A., & Tsai, S.-J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081689 · Cited by 282
Increased risk of Parkinson’s disease after depression: A retrospective cohort study
Schuurman, A. G., van den Akker, M., Ensinck, K. T. J. L., Metsemakers, J. F. M., Knottnerus, J. A., Leentjens, A. F. G., & Buntinx, F. (2002) · Neurology · doi:10.1212/wnl.58.10.1501 · Cited by 275
Serotonin, inhibition, and negative mood
Dayan, P., & Huys, Q. J. M. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0040004 · Cited by 263
“First, 5-HT is involved in the prediction of aversive events, possibly as a form of opponent [1–3] to dopamine [4–11].”
Neuropsychiatry of the basal ganglia
Ring, H. A. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.1.12 · Cited by 270
Reward and the serotonergic system
Kranz, G. S., Kasper, S., & Lanzenberger, R. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.036 · Cited by 267
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Li, P., L. Snyder, G., & E. Vanover, K. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160608084834 · Cited by 266
Luciana, M. (1998) · Cerebral Cortex · doi:10.1093/cercor/8.3.218 · Cited by 265
Anticevic, A., Gancsos, M., Murray, J. D., Repovs, G., Driesen, N. R., Ennis, D. J., Niciu, M. J., Morgan, P. T., Surti, T. S., Bloch, M. H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208494109 · Cited by 243
Shiloh, R., Zemishlany, Z., Aizenberg, D., Radwan, M., Schwartz, B., Dorfman-Etrog, P., Modai, I., Khaikin, M., & Weizman, A. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.569 · Cited by 260
A review of the role of serotonin receptors in psychiatric disorders
Naughton, M., Mulrooney, J. B., & Leonard, B. E. (2000) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/1099-1077(200008)15:6<397::aid-hup212>3.0.co;2-l · Cited by 258
Organization of monosynaptic inputs to the serotonin and dopamine neuromodulatory systems
Ogawa, S. K., Cohen, J. Y., Hwang, D., Uchida, N., & Watabe-Uchida, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.042 · Cited by 249
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison
Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., Tossell, J. W., Lenane, M., & Rapoport, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.721 · Cited by 225
Feng, J., Cai, X., Zhao, J., & Yan, Z. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06502.2001 · Cited by 212
Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy
Markowitz, J. S., Brown, C. S., & Moore, T. R. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.17215 · Cited by 208
Medina, M. Á., Urdiales, J. L., Rodríguez-Caso, C., Ramírez, F. J., & Sánchez-Jiménez, F. (2003) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/713609209 · Cited by 198
Woody, E. Z., & Szechtman, H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.08.003 · Cited by 195
Wang, H.-L., Zhang, S., Qi, J., Wang, H., Cachope, R., Mejias-Aponte, C. A., Gomez, J. A., Mateo-Semidey, G. E., Beaudoin, G. M. J., Paladini, C. A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.014 · Cited by 176
Obsessive–compulsive disorder comorbidity: Clinical assessment and therapeutic implications
Pallanti, S., Grassi, G., Sarrecchia, E. D., Cantisani, A., & Pellegrini, M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00070 · Cited by 158
“A possible explanation of this phenomenon could be the involvement of 5HT2A receptors and the disruption of the interaction of serotonin and dopamine within the cortico-striato-thalamocortical loops (Kapur and Remington, 1996).”
BackgroundNeurobiology of Obsessive-Compulsive Disorder:Serotonin and Beyond
Westenberg, H. G. M., Fineberg, N. A., & Denys, D. (2007) · CNS Spectrums · doi:10.1017/s1092852900002479 · Cited by 148
KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00910-2 · Cited by 146
Dougherty, D. D., Brennan, B. P., Stewart, S. E., Wilhelm, S., Widge, A. S., & Rauch, S. L. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0930 · Cited by 131
Madhusoodanan, S., Alexeenko, L., Sanders, R., & Brenner, R. (2010) · Annals of Clinical Psychiatry · doi:10.1177/104012371002200303 · Cited by 121
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Yan, Z. (2002) · Molecular Neurobiology · doi:10.1385/mn:26:2-3:203 · Cited by 100
Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia
Martin-Ruiz, C. M., Haroutunian, V. H., Long, P., Young, A. H., Davis, K. L., Perry, E. K., & Court, J. A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00348-2 · Cited by 100
Acute serotonin and dopamine depletion improves attentional control: findings from the Stroop task
Scholes, K. E., Harrison, B. J., O'Neill, B. V., Leung, S., Croft, R. J., Pipingas, A., Phan, K. L., & Nathan, P. J. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301262 · Cited by 86
Sakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., Horiguchi, Y., & Taguchi, K. (2015) · Biological ^|^ Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00315 · Cited by 81
Morein-Zamir, S., Craig, K. J., Ersche, K. D., Abbott, S., Muller, U., Fineberg, N. A., Bullmore, E. T., Sahakian, B. J., & Robbins, T. W. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1963-z · Cited by 54
Heidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000043 · Cited by 48
Miodownik, C., Lerner, V., Statsenko, N., Dwolatzky, T., Nemets, B., Berzak, E., & Bergman, J. (2006) · Clinical Neuropharmacology · doi:10.1097/00002826-200603000-00002 · Cited by 47
Lehmann, K., Lesting, J., Polascheck, D., & Teuchert-Noodt, G. (2003) · Developmental Brain Research · doi:10.1016/s0165-3806(03)00130-5 · Cited by 42
A predictive coding framework for understanding major depression
Gilbert, J. R., Wusinich, C., & Zarate, C. A. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.787495 · Cited by 38
Can long-term antidepressant use be depressogenic?
El-Mallakh, R. S., Waltrip, C., & Peters, C. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0412e · Cited by 14
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1996-04-01
- Volume
- 153
- Issue
- 4
- Pages
- 466-476
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2401206973
- Cited by
- 823
- References
- 3
- FWCI
- 45.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.